국가: 헝가리
언어: 영어
출처: HMA (Heads of Medicines Agencies)
marbofloxacin 80 mg
Krka d.d.
QJ01MA93
Tablet
marbofloxacin
Dogs
2012-11-21
Issued: April 2013 AN: 01881/2011 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marfloxin 80 mg tablets for dogs Quiflox 80 mg tablets for dogs Quiflox vet 80 mg tablets for dogs Marbiflox 80 mg tablets for dogs Marfloxin 80 mg tablets for dogs (Austria, Belgium, Bulgaria, Estonia, Germany, Greece, Italy, Ireland, Netherlands, Poland, Portugal, Romania, Slovenia, Spain, United Kingdom) Quiflox 80 mg tablets for dogs (Czech Republic, Hungary, Latvia, Lithuania, Slovak Republic) Quiflox vet 80 mg tablets for dogs (Sweden, Finland, Norway) Marbiflox 80 mg tablets for dogs (Denmark, France) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: ACTIVE SUBSTANCE: Marbofloxacin…….80 mg EXCIPIENTS: For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablets. Light brownish yellow, capsule shaped, biconvex, marble tablets with possible dark and white spots and scored on the both sides. The tablets can be divided into halves. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of infections caused by strains of microorganisms susceptible to marbofloxacin in dogs: skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis); urinary tract infections (UTI) associated or not with prostatitis or epididymitis; respiratory tract infections. Issued: April 2013 AN: 01881/2011 Page 2 of 6 4.3 CONTRAINDICATIONS Do not use in dogs aged less than 12 mo 전체 문서 읽기